Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Qiagen ( (QGEN) ).
Qiagen announced that the Dutch Authority for the Financial Markets (AFM) has disclosed a notification regarding voting rights in the company held by Barclays Plc and its affiliates as of January 22, 2026. According to the filing, Barclays’ aggregate position in Qiagen amounts to 3.26% of both capital interest and voting rights, comprised of a mix of real and potential holdings in ordinary shares, pledged shares, equity swaps, contracts for difference, convertible bonds and other derivatives, all held indirectly via various Barclays entities. The notification reflects a notable institutional stake in Qiagen, signaling continued interest from major financial players, although Qiagen emphasized it is not responsible for the accuracy of the AFM disclosure, which originates from the regulator’s public register.
The most recent analyst rating on (QGEN) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, the Netherlands, is a life sciences and molecular diagnostics company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, giving it broad access to international capital markets and a diverse investor base.
Average Trading Volume: 1,827,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.17B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.